Nociceptin is present in synovial fluid of patients undergoing total knee arthroplasty

Thomas A Verbeek, Nancy Ruth Jarbadan, Charles Davis, Julia Caldwell, Thomas A Verbeek, Nancy Ruth Jarbadan, Charles Davis, Julia Caldwell

Abstract

Background: Osteoarthritis is a mechanical abnormality characterized by chronic joint pain associated with degeneration of the articular cartilage, synovitis, and local inflammation, leading to loss of function and pain. A connection exists between the peripheral nervous system and inflammatory joint degeneration. The process by which inflammation is influenced by the nervous system is known as neuroinflammation. One of the neuropeptides involved in peripheral neuroinflammation is nociceptin, a peptide related to the opioid class of substances. Nociceptin has both pro- and anti-inflammatory effects. Some studies show that nociceptin can be measured in synovial fluid, while other studies have not been able to detect it. The presence of nociceptin in synovial fluid could imply a molecular role for the neuropeptide in the joint, both physiologically as well as pathophysiologically. The goal of this pilot study was to determine whether nociceptin was present in the synovial fluid of osteoarthritic knees.

Methods: Patients undergoing primary total knee arthroplasty were enrolled after Institutional Review Board approval was obtained. Synovial fluid was aspirated from patients' operative knee joints and blood samples were obtained. A commercially available enzyme Immunoassay kit was used to test for nociceptin. A linear mixed-effects model was developed to account for the repeated measurements and baseline covariates. Least squares (adjusted) means were derived from the model to compare the sample types and to compare subgroups.

Results: Twenty patients were included in this study. Nociceptin was detected in the synovial fluid and plasma of all patients. The mean concentration (± standard deviation) of nociceptin in synovial fluid was 28.7 ± 18.2 pg/ml. The mean concentration of nociceptin in plasma was 45.2 ± 24.3 pg/ml pre-procedure, and 40.1 ± 20.6 pg/ml post-tourniquet deflation. The nociceptin concentration in synovial fluid was significantly lower than the nociceptin concentration in plasma, both pre-procedure and post-tourniquet deflation (p = 0.002 and p = 0.016 respectively). The nociceptin concentration in both plasma and synovial fluid was significantly lower in females versus males (p = 0.012).

Conclusion: We demonstrated that nociceptin is present in synovial fluid and plasma of patients undergoing total knee arthroplasty. This implies a potential role for nociceptin in modulating inflammation in osteoarthritis.

Trial registration: ClinicalTrials.gov , NCT02528916 . Retrospectively registered on August 19, 2015.

Keywords: Arthroplasty; Neuroinflammation; Nociceptin; Orphanin FQ; Osteoarthritis.

Conflict of interest statement

None of the authors report any conflict of interest.

References

    1. Pereira D, Peleteiro B, Araújo J, Branco J, Santos RA, Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage. 2011;19:1270–1285. doi: 10.1016/j.joca.2011.08.009.
    1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81:646–656.
    1. Hiligsmann M, Cooper C, Arden N, et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Semin Arthritis Rheum. 2013;43:303–313. doi: 10.1016/j.semarthrit.2013.07.003.
    1. Glyn-Jones S, Palmer AJ, Agricola R, et al. Osteoarthritis. Lancet. 2015;386:376–387. doi: 10.1016/S0140-6736(14)60802-3.
    1. Saberi Hosnijeh F, Bierma-Zeinstra SM, Bay-Jensen AC. Osteoarthritis year in review 2018: biomarkers (biochemical markers) Osteoarthritis Cartilage. 2019;27:412–423. doi: 10.1016/j.joca.2018.12.002.
    1. David Clark J, Tawfik VL, Tajerian M, Kingery WS. Autoinflammatory and autoimmune contributions to complex regional pain syndrome. Mol Pain. 2018;14:1744806918799127. doi: 10.1177/1744806918799127.
    1. Fusco M, Skaper SD, Coaccioli S, Varrassi G, Paladini A. Degenerative joint diseases and neuroinflammation. Pain Pract. 2017;17:522–532. doi: 10.1111/papr.12551.
    1. Inoue M, Kobayashi M, Kozaki S, Zimmer A, Ueda H. Nociceptin/orphanin FQ-induced nociceptive responses through substance P release from peripheral nerve endings in mice. Proc Natl Acad Sci U S A. 1998;95:10949–10953. doi: 10.1073/pnas.95.18.10949.
    1. Helyes Z, Németh J, Pintér E, Szolcsányi J. Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol. 1997;121:613–615. doi: 10.1038/sj.bjp.0701209.
    1. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995;377:532–535. doi: 10.1038/377532a0.
    1. Fiset ME, Gilbert C, Poubelle PE, Pouliot M. Human neutrophils as a source of nociceptin: a novel link between pain and inflammation. Biochemistry. 2003;42:10498–10505. doi: 10.1021/bi0300635.
    1. Mathis JP, Mandyam CD, Altememi GF, Pasternak GW, Standifer KM. Orphanin FQ/nociceptin and naloxone benzoylhydrazone activate distinct receptors in BE (2)-C human neuroblastoma cells. Neurosci Lett. 2001;299:173–176. doi: 10.1016/S0304-3940(01)01524-5.
    1. Mamiya T, Noda Y, Ren X, et al. Morphine tolerance and dependence in the nociceptin receptor knockout mice. J Neural Transm (Vienna) 2001;108:1349–1361. doi: 10.1007/s007020100012.
    1. Meunier JC. Utilizing functional genomics to identify new pain treatments : the example of nociceptin. Am J Pharmacogenomics. 2003;3:117–130. doi: 10.2165/00129785-200303020-00005.
    1. Kumar N, Smart D, Mason S, McKnight AT, Rowbotham DJ, Lambert DG. Neither nociceptin nor its receptor are present in human synovial fluid or tissue. Br J Anaesth. 1999;83:470–471. doi: 10.1093/bja/83.3.470.
    1. Kleideiter E, Piana C, Wang S, Nemeth R, Gautrois M. Clinical pharmacokinetic characteristics of cebranopadol, a novel first-in-class analgesic. Clin Pharmacokinet. 2018;57:31–50. doi: 10.1007/s40262-017-0545-1.
    1. Breivik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. Br J Anaesth. 2008;101:17–24. doi: 10.1093/bja/aen103.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of biomedical informatics. 2009;42:377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Ertsey C, Hantos M, Bozsik G, Tekes K. Circulating nociceptin levels during the cluster headache period. Cephalalgia. 2004;24:280–283. doi: 10.1111/j.1468-2982.2004.00664.x.
    1. Ko MH, Kim YH, Woo RS, Kim KW. Quantitative analysis of nociceptin in blood of patients with acute and chronic pain. Neuroreport. 2002;13:1631–1633. doi: 10.1097/00001756-200209160-00012.
    1. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL., 3rd Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009;10:447–485. doi: 10.1016/j.jpain.2008.12.001.
    1. Holtzman J, Saleh K, Kane R. Gender differences in functional status and pain in a Medicare population undergoing elective total hip arthroplasty. Med Care. 2002;40:461–470. doi: 10.1097/00005650-200206000-00003.
    1. Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage. 2005;13:769–781. doi: 10.1016/j.joca.2005.04.014.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe